HUTCHMED (China) Limited Sponsored ADR $HCM Shares Sold by Amundi

Amundi decreased its holdings in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 7.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 157,432 shares of the company’s stock after selling 12,818 shares during the quarter. Amundi owned 0.09% of HUTCHMED worth $2,401,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Crossmark Global Holdings Inc. raised its holdings in HUTCHMED by 31.4% in the 1st quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company’s stock worth $367,000 after purchasing an additional 5,829 shares during the period. Bank of America Corp DE increased its stake in HUTCHMED by 40.4% during the 4th quarter. Bank of America Corp DE now owns 22,723 shares of the company’s stock worth $327,000 after buying an additional 6,540 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in HUTCHMED by 49.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company’s stock worth $39,000 after buying an additional 899 shares in the last quarter. Barclays PLC increased its stake in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after buying an additional 2,255 shares in the last quarter. Finally, Vident Advisory LLC increased its stake in HUTCHMED by 78.3% during the 1st quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock worth $297,000 after buying an additional 8,664 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Up 4.2%

NASDAQ:HCM opened at $16.37 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. The stock’s fifty day moving average is $16.42 and its two-hundred day moving average is $15.40. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $21.50.

Analysts Set New Price Targets

HCM has been the subject of several research reports. Zacks Research lowered HUTCHMED from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Bank of America boosted their price objective on HUTCHMED from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. Finally, Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, HUTCHMED currently has a consensus rating of “Hold” and an average target price of $28.00.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.